Abstract
Neurological disorders, such as epilepsy, dementia, Parkinson’s disease and Alzheimer’s disease, occur due to disorganization of the neurons in the nervous system. Disturbances in the nervous system cause problems with the memory, senses and moods. In order to treat such disorders, scientists have been working extensively, utilizing different approaches. Nanoneurotechnology has emerged as a promising tool to manage these complicated disorders, where nanoparticles with their tunable properties such as size, shape, increased solubility, biodegradability, surface area and sharp penetration through the biological barriers, target the central nervous system. This technology targets damaged neurons without affecting healthy neurons and the Blood-Brain Barrier (BBB). In this review, we discuss neurological disorders and challenges in their diagnosis and treatment by emphasizing on the role of tailorable gold nanoparticles in therapeutic drug approaches.
Keywords: Neurodegeneration, blood brain barrier, nanotechnology, gold nanoparticles, neurological disorders, therapeutic drug approaches.
Graphical Abstract
Current Drug Metabolism
Title:New Horizons in the Treatment of Neurological Disorders with Tailorable Gold Nanoparticles
Volume: 22 Issue: 12
Author(s): Farheen , Md. Asad Khan*, Ghulam Md. Ashraf, Anwar L. Bilgrami and M. Moshahid A. Rizvi
Affiliation:
- Department of Biochemistry, Faculty of Dentistry, Jamia Millia Islamia, New Delhi, India
Keywords: Neurodegeneration, blood brain barrier, nanotechnology, gold nanoparticles, neurological disorders, therapeutic drug approaches.
Abstract: Neurological disorders, such as epilepsy, dementia, Parkinson’s disease and Alzheimer’s disease, occur due to disorganization of the neurons in the nervous system. Disturbances in the nervous system cause problems with the memory, senses and moods. In order to treat such disorders, scientists have been working extensively, utilizing different approaches. Nanoneurotechnology has emerged as a promising tool to manage these complicated disorders, where nanoparticles with their tunable properties such as size, shape, increased solubility, biodegradability, surface area and sharp penetration through the biological barriers, target the central nervous system. This technology targets damaged neurons without affecting healthy neurons and the Blood-Brain Barrier (BBB). In this review, we discuss neurological disorders and challenges in their diagnosis and treatment by emphasizing on the role of tailorable gold nanoparticles in therapeutic drug approaches.
Export Options
About this article
Cite this article as:
Farheen , Khan Asad Md. *, Ashraf Md. Ghulam , Bilgrami L. Anwar and Rizvi Moshahid A. M. , New Horizons in the Treatment of Neurological Disorders with Tailorable Gold Nanoparticles, Current Drug Metabolism 2021; 22 (12) . https://dx.doi.org/10.2174/1389200222666210525123416
DOI https://dx.doi.org/10.2174/1389200222666210525123416 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of the Brain Renin-Angiotensin System in Neurodegenerative Disorders
Current Alzheimer Research Hormonal Control of the Neuropeptide Y System
Current Protein & Peptide Science Malignant Mesothelioma: Cell Survival Pathways and Radiation Therapy
Current Respiratory Medicine Reviews Nanowired Drug Delivery Across the Blood-Brain Barrier in Central Nervous System Injury and Repair
CNS & Neurological Disorders - Drug Targets Anti-inflammatory strategies in stroke: a potential therapeutic target
Current Vascular Pharmacology Matrix Gelatinases in Atherosclerosis and Diabetic Nephropathy: Progress and Challenges
Current Vascular Pharmacology Targeting Vascular Changes in Lesions in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
Central Nervous System Agents in Medicinal Chemistry Functions of Fukutin, a Gene Responsible for Fukuyama Type Congenital Muscular Dystrophy, in Neuromuscular System and Other Somatic Organs
Central Nervous System Agents in Medicinal Chemistry Physiology and Pharmacology of the Vanilloid Receptor
Current Neuropharmacology OX40:OX40L Axis: Emerging Targets for Immunotherapy of Human Disease
Current Immunology Reviews (Discontinued) Tetracyclines and Pulmonary Inflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets A Contemporary Approach to Macular Edema Treatment in Retinal Vein Occlusion
Vascular Disease Prevention (Discontinued) Remyelination in Multiple Sclerosis: The Therapeutic Potential of Neural and Mesenchymal Stem/Progenitor Cells
Current Signal Transduction Therapy How Satiety Factors Reach CNS Appetite Centers
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Cell Culture in Microfluidic Systems
Micro and Nanosystems Anticancer Mammalian Target of Rapamycin (mTOR) Signaling Pathway Inhibitors: Current Status, Challenges and Future Prospects in Management of Epilepsy
CNS & Neurological Disorders - Drug Targets The Valsalva Maneuver and Alzheimers Disease: Is there a link?
Current Alzheimer Research Platelets in Alzheimer’s Disease-Associated Cellular Senescence and Inflammation
Current Pharmaceutical Design Metabotropic Glutamate Receptors: A Review on Prospectives and Therapeutic Aspects
Mini-Reviews in Medicinal Chemistry Down with the Erythropoietin. Long Live the Erythropoietin !
Current Drug Targets